Topic
Philogen
Global News
1 Oct 2024
Sun Pharma, Philogen in agreement to commercialise speciality product FIBROMUN
Fibromun is an anti-cancer immunotherapy Sun Pharmaceutical Industries and Philogen have entered into a global licensing agreement for commercialising Philogen’s…
Global News
30 May 2023
Sun Pharma, Philogen in agreement to commercialise NIDLEGY in Europe, Australia, New Zealand
Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the…